CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a report published on Saturday morning. The firm issued a sell rating on the stock.

CEL-SCI Price Performance

CEL-SCI stock opened at $0.24 on Friday. The company has a market cap of $19.12 million, a P/E ratio of -0.50 and a beta of 0.67. CEL-SCI has a one year low of $0.23 and a one year high of $2.39. The business has a fifty day moving average of $0.36 and a two-hundred day moving average of $0.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Hedge Funds Weigh In On CEL-SCI

Several hedge funds have recently bought and sold shares of the company. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI in the third quarter valued at $98,000. Thoroughbred Financial Services LLC boosted its position in shares of CEL-SCI by 40.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the last quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.